Quantitation Assay for Biologics Sample Testing

The ValitaCell IgG titer assay from Molecular Devices complements the company’s  workflow solution for cell line development by offering a 10-minute titer assay that can be run on the company’s SpectraMax series of microplate readers.

Producing rapid results compared to HPLC, ELISA, and Biolayer Interferometry, ValitaTiter is the most efficient assay for minimising cost and time to results because it works in the presence of cells, minimises dilutions, eliminates wash steps, and easily integrates into automated high-throughput cell line development and process development workflows. Integrating ValitaTiter and Molecular Devices fluorescence polarisation plate readers produce a seamless IgG titer assay setup and optimisation process allowing teams to realise savings on time and resources as well as faster time-to-market. 

Molecular Devices’ technical support team and PhD-level field application scientists partner with their customers to create complete automated workflows to shorten the time to market for critical vaccines and therapeutics. This workflow will now include the ValitaTiter IgG assay. Molecular Devices’ long history of developing regulatory compliance solutions and software will ensure a streamlined regulatory and validation process. 

“Integrating ValitaTiter gives us a great opportunity to expand our cell line development workflow even further, to bring therapeutics to market faster,” said Terrell Mathews, Vice President of Global Sales at Molecular Devices. “Using ValitaTiter with our SpectraMax microplate readers, SoftMax Pro Software, and automation solutions further enhances the reliability and reproducibility of assay results and enables seamless integration of the assay in regulated workflows.”

More information online